Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IronKiller

Financiado

Joining the forces of Natural Killer Cells and Ferroptosis to treat Refractory N...

Joining the forces of Natural Killer Cells and Ferroptosis to treat Refractory Neuroblastoma Neuroblastoma (NB), a rare paediatric solid tumour, accounts for 15% of childhood cancer deaths. Immunotherapy has improved the survival for haematological malignancies, but solid tumours remain a challenge. The high heterogeneity... ver más

31/08/2025

FUNDACIÓN PARA LA...

165K€

Presupuesto del proyecto: 165K€

Líder del proyecto

FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA. HO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 4M€

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-08-29

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

FUNDACIÓN PARA LA INVESTIGAC...

165.31K€ | Lider

UCLM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

SAF2017-83732-R REPROGRAMACION DEL MICROAMBIENTE TUMORAL PARA AUMENTAR LA EF... 339K€ Cerrado

immunoMet Deciphering immune evasion mechanisms of metastatic cancer c... 184K€ Cerrado

CANCER-DC Dissecting Regulatory Networks That Mediate Dendritic Cell S... 2M€ Cerrado

CD20CARNAPT iTANK: a nuniversal technology to boost the efficacy of CAR... 4M€ Cerrado

LiveBioThx Live biotherapeutics to potentiate cancer immunotherapy 150K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2022-08-29
Fecha Fin: 2025-08-31

Líder del proyecto

FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA. HO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 4M€

Presupuesto del proyecto 165K€

Descripción del proyecto Neuroblastoma (NB), a rare paediatric solid tumour, accounts for 15% of childhood cancer deaths. Immunotherapy has improved the survival for haematological malignancies, but solid tumours remain a challenge. The high heterogeneity, low mutational load, and strong immunosuppressive tumour microenvironment (i-TME) have hindered the success of immunotherapy in NB. Recently, natural killer (NK) cells have stood as a promising immunotherapeutic tool, as they don’t depend on specific mutations. Still, clinical trials for NB show only modest results, proving further action is needed to overcome the iTME. Late findings show that refractory tumours often respond to Ferroptosis, a novel cell death mechanism that is highly immunogenic. Cancer cells undergoing ferroptosis release HMGB1 and other well-known recruiters of NK cells. Moreover, ferroptotic drugs can act through several mechanisms and can be adapted to patients with different tumour characteristics. The goal of IronKiller is to combine ferroptotic drugs with NK cell therapy to treat refractory NB, and to perform in silico modelling of the results to predict which patients would benefit from this novel therapy. I am an experienced biologist and engineer joining a clinical research group strong in immunotherapies. We will follow an in vitro-in vivo-in silico strategy that will cover a variety of disciplines, from basic biology and pre-clinical research, all the way to bioinformatics and machine learning. I will reinforce my experience in cell death mechanisms and translational research, and I will also acquire new knowledge and skills in the areas of cell immunotherapy and oncological mathematical modelling. The latter through a secondment at an academic institution. Along with the research work, the diverse training, management and communication activities planned, will play a key role in advancing my professional development towards becoming an independent academic group leader in translational cancer research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores